1. Flavone 8-acetic acid: our current understanding of its mechanism of action in solid tumours

   • Jeffrey Cummings
   • John F. Smyth

   Review Pages: 269 - 272

2. Flavone acetic acid (LM-975; NSC-347512) activation to cytotoxic species in vivo and in vitro

   • Guy G. Chabot
   • Marie-Christine Bissery
   • Alain Gouyette

   Original Articles Pages: 273 - 276

3. Preclinical pharmacologic studies of the new antitumor agent carmethizole (NSC-602668) in the mouse and beagle dog

   • Joanne I. Brodfuehrer
   • Tracy J. Wilke
   • Garth Powis

   Original Articles Pages: 277 - 283

4. Identification of anthracyclines and related agents that retain preferential activity over Adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A

   • Helen M. Coley
   • Peter R. Twentyman
   • Paul Workman

   Original Articles Pages: 284 - 290

5. Prediction of thioguanine-induced cytotoxicity by dual-parameter flow cytometric analysis

   • Jonathan Maybaum
   • Paul Ting
   • Clare E. Rogers

   Original Articles Pages: 291 - 294

6. Comparison of tetrazolium colorimetric and [³H]-uridine assays for in vitro chemosensitivity testing

   • Christopher H. J. Ford
   • Vernon J. Richardson
   • Georgia Tsaltas

   Original Articles Pages: 295 - 301

7. Effects of two pyridinalalkyliminerhodium(I) complexes in mice bearing MCa mammary carcinoma

   • Gianni Sava
   • Sonia Zorzet
   • Grazia Zassinovich

   Original Articles Pages: 302 - 306

8. Differential interactions of traditional and novel antiemetics with dopamine D₂ and 5-hydroxytryptamine₃ receptors

   • Anne Hamik
   • Stephen J. Peroutka

   Original Articles Pages: 307 - 310

9. Absence of cross-resistance between two alkylating agents: BCNU vs bifunctional galactitol

   • Etel Institóris
   • Károly Szikla
   • Ferenc Gál

   Original Articles Pages: 311 - 313

10. A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics

    • Louise B. Grochow
    • Dennis A. Noe
    • Ross C. Donehower

    Original Articles Pages: 314 - 320

11. Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer

    • R. L. Souhami
    • H. T. Hajichristou
    • J. S. Tobias

    Original Articles Pages: 321 - 325

12. Alternating six-drug combination chemotherapy induction for intermediate and high-grade non-Hodgkin's lymphoma

    • John A. Green
    • R. Douglas Errington
    • Hilmar M. Warenius

    Original Articles Pages: 326 - 328

13. The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation

    • Maurice L. Slevin
    • Simon P. Joel
    • Peter F. M. Wrigley

    Original Articles Pages: 329 - 331

14. Pharmacokinetic and pharmacodynamic studies with 4′-epi-doxorubicin in nasopharyngeal carcinoma patients

    • Oliver Yoa-Pu Hu
    • Shiu-Pei Chang
    • Kuang-Yao Chen

    Original Articles Pages: 332 - 337

15. VP-16, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen

    • R. Herbrecht
    • J. J. Garcia
    • F. Oberling

    Short Communication Pages: 338 - 339

16. Meeting announcement

    Announcement Pages: 340 - 340